开窗Anaconda™能挽救失败的竞争对手植入术吗?国际参照系

IF 0.7 Q3 Medicine
Matti Jubouri, Abdelaziz O Surkhi, Sven Z C P Tan, Damian M Bailey, Ian M Williams, Mohamad Bashir
{"title":"开窗Anaconda™能挽救失败的竞争对手植入术吗?国际参照系","authors":"Matti Jubouri,&nbsp;Abdelaziz O Surkhi,&nbsp;Sven Z C P Tan,&nbsp;Damian M Bailey,&nbsp;Ian M Williams,&nbsp;Mohamad Bashir","doi":"10.1177/02184923221138505","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>An abdominal aortic aneurysm (AAA) is a life-threatening abnormal dilation of the abdominal aorta that can be repaired either endovascularly or with open surgery. However, endovascular aortic repair (EVAR) has become the main treatment modality for AAA due to its more optimal results. EVAR devices can either be standard, fenestrated, or branched, with fenestrated EVAR (FEVAR) seemingly achieving superior prospects. Although EVAR is associated with excellent outcomes, it still carries a risk of certain complications requiring reintervention or 'rescue'. Several commercial EVAR devices are available on the global market, nevertheless, the Fenestrated Anaconda developed by Terumo Aortic can be considered the superior device due to the wide range of endovascular solutions that it offers along with its unique custom-made approach, excellent results and its highly promising potential to be used as a 'rescue' device for failed competitor endografts.</p><p><strong>Materials and methods: </strong>The current study represents a 9-year cross-sectional international analysis of a custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R were utilised. Pearson Chi-square analysis was used to assess differences in cumulative distribution frequencies between select variables. Statistical significance for all two-tailed tests was set at <i>p</i> < 0.05.</p><p><strong>Results: </strong>Out of 5058 EVARs performed using the Fenestrated Anaconda, 2987 (59%) were 'rescue' procedures for migrated Gore (<i>n</i> = 252) and Medtronic (<i>n</i> = 2735) devices. The Fenestrated Anaconda™ was indicated as the reintervention device either due to unsuitable/complex anatomy for the competitor (<i>n</i> = 2411) or based on surgeon preference (<i>n</i> = 576). Overall, the Fenestrated Anaconda was utilised to rescue 3466 (68.5%) failed previous EVARs using competitor devices. Yet, the primary endovascular solution offered by the Fenestrated Anaconda was FEVAR (91.3%), with 112 (2.2%) devices using custom-made iliac stents.</p><p><strong>Discussion: </strong>The use of the Fenestrated Anaconda endograft as a 'rescue' device to salvage failed competitor devices is well-established in the literature with excellent clinical outcomes achieved. The evidence in the literature also highlights the distinctive custom-made approach that the Fenestrated Anaconda offers which enables it to treat extremely complex aortic anatomy.</p>","PeriodicalId":35950,"journal":{"name":"ASIAN CARDIOVASCULAR & THORACIC ANNALS","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Can the Fenestrated Anaconda™ salvage failed competitor endografts? An international frame of reference.\",\"authors\":\"Matti Jubouri,&nbsp;Abdelaziz O Surkhi,&nbsp;Sven Z C P Tan,&nbsp;Damian M Bailey,&nbsp;Ian M Williams,&nbsp;Mohamad Bashir\",\"doi\":\"10.1177/02184923221138505\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>An abdominal aortic aneurysm (AAA) is a life-threatening abnormal dilation of the abdominal aorta that can be repaired either endovascularly or with open surgery. However, endovascular aortic repair (EVAR) has become the main treatment modality for AAA due to its more optimal results. EVAR devices can either be standard, fenestrated, or branched, with fenestrated EVAR (FEVAR) seemingly achieving superior prospects. Although EVAR is associated with excellent outcomes, it still carries a risk of certain complications requiring reintervention or 'rescue'. Several commercial EVAR devices are available on the global market, nevertheless, the Fenestrated Anaconda developed by Terumo Aortic can be considered the superior device due to the wide range of endovascular solutions that it offers along with its unique custom-made approach, excellent results and its highly promising potential to be used as a 'rescue' device for failed competitor endografts.</p><p><strong>Materials and methods: </strong>The current study represents a 9-year cross-sectional international analysis of a custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R were utilised. Pearson Chi-square analysis was used to assess differences in cumulative distribution frequencies between select variables. Statistical significance for all two-tailed tests was set at <i>p</i> < 0.05.</p><p><strong>Results: </strong>Out of 5058 EVARs performed using the Fenestrated Anaconda, 2987 (59%) were 'rescue' procedures for migrated Gore (<i>n</i> = 252) and Medtronic (<i>n</i> = 2735) devices. The Fenestrated Anaconda™ was indicated as the reintervention device either due to unsuitable/complex anatomy for the competitor (<i>n</i> = 2411) or based on surgeon preference (<i>n</i> = 576). Overall, the Fenestrated Anaconda was utilised to rescue 3466 (68.5%) failed previous EVARs using competitor devices. Yet, the primary endovascular solution offered by the Fenestrated Anaconda was FEVAR (91.3%), with 112 (2.2%) devices using custom-made iliac stents.</p><p><strong>Discussion: </strong>The use of the Fenestrated Anaconda endograft as a 'rescue' device to salvage failed competitor devices is well-established in the literature with excellent clinical outcomes achieved. The evidence in the literature also highlights the distinctive custom-made approach that the Fenestrated Anaconda offers which enables it to treat extremely complex aortic anatomy.</p>\",\"PeriodicalId\":35950,\"journal\":{\"name\":\"ASIAN CARDIOVASCULAR & THORACIC ANNALS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ASIAN CARDIOVASCULAR & THORACIC ANNALS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/02184923221138505\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ASIAN CARDIOVASCULAR & THORACIC ANNALS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02184923221138505","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

腹主动脉瘤(AAA)是一种危及生命的腹主动脉异常扩张,可以通过血管内或开放手术修复。然而,血管内主动脉修复(EVAR)因其效果更佳而成为AAA的主要治疗方式。EVAR装置可以是标准的、开孔的或分支的,其中开孔EVAR (FEVAR)似乎具有更好的前景。尽管EVAR与良好的预后相关,但它仍然存在某些并发症的风险,需要再次干预或“抢救”。全球市场上有几种商用EVAR设备,然而,Terumo Aortic开发的feneated Anaconda可以被认为是一种优越的设备,因为它提供了广泛的血管内解决方案,以及独特的定制方法,出色的效果,以及作为失败的竞争对手内移植物的“抢救”设备的巨大潜力。材料和方法:目前的研究是对定制的开窗Anaconda™装置进行的为期9年的横断面国际分析。采用SPSS 28 For Windows和R软件进行统计分析。使用Pearson卡方分析来评估所选变量之间累积分布频率的差异。所有双侧检验的统计学意义均为p < 0.05。结果:在使用开窗Anaconda进行的5058例EVARs中,2987例(59%)为迁移Gore (n = 252)和Medtronic (n = 2735)器械的“抢救”手术。由于竞争对手的解剖结构不合适或复杂(n = 2411),或基于外科医生的偏好(n = 576),我们选择了开窗Anaconda™作为再介入装置。总体而言,使用开窗Anaconda挽救了3466例(68.5%)先前使用竞争对手设备失败的EVARs。然而,开腔蟒蛇提供的主要血管内解决方案是FEVAR(91.3%),其中112个(2.2%)装置使用定制的髂支架。讨论:使用开窗Anaconda内移植物作为“抢救”装置来挽救失败的竞争对手装置在文献中得到了良好的临床效果。文献中的证据也强调了开窗水蟒提供的独特的定制方法,使其能够治疗极其复杂的主动脉解剖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Can the Fenestrated Anaconda™ salvage failed competitor endografts? An international frame of reference.

Introduction: An abdominal aortic aneurysm (AAA) is a life-threatening abnormal dilation of the abdominal aorta that can be repaired either endovascularly or with open surgery. However, endovascular aortic repair (EVAR) has become the main treatment modality for AAA due to its more optimal results. EVAR devices can either be standard, fenestrated, or branched, with fenestrated EVAR (FEVAR) seemingly achieving superior prospects. Although EVAR is associated with excellent outcomes, it still carries a risk of certain complications requiring reintervention or 'rescue'. Several commercial EVAR devices are available on the global market, nevertheless, the Fenestrated Anaconda developed by Terumo Aortic can be considered the superior device due to the wide range of endovascular solutions that it offers along with its unique custom-made approach, excellent results and its highly promising potential to be used as a 'rescue' device for failed competitor endografts.

Materials and methods: The current study represents a 9-year cross-sectional international analysis of a custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R were utilised. Pearson Chi-square analysis was used to assess differences in cumulative distribution frequencies between select variables. Statistical significance for all two-tailed tests was set at p < 0.05.

Results: Out of 5058 EVARs performed using the Fenestrated Anaconda, 2987 (59%) were 'rescue' procedures for migrated Gore (n = 252) and Medtronic (n = 2735) devices. The Fenestrated Anaconda™ was indicated as the reintervention device either due to unsuitable/complex anatomy for the competitor (n = 2411) or based on surgeon preference (n = 576). Overall, the Fenestrated Anaconda was utilised to rescue 3466 (68.5%) failed previous EVARs using competitor devices. Yet, the primary endovascular solution offered by the Fenestrated Anaconda was FEVAR (91.3%), with 112 (2.2%) devices using custom-made iliac stents.

Discussion: The use of the Fenestrated Anaconda endograft as a 'rescue' device to salvage failed competitor devices is well-established in the literature with excellent clinical outcomes achieved. The evidence in the literature also highlights the distinctive custom-made approach that the Fenestrated Anaconda offers which enables it to treat extremely complex aortic anatomy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
78
期刊介绍: The Asian Cardiovascular and Thoracic Annals is an international peer-reviewed journal pertaining to cardiovascular and thoracic medicine. Besides original clinical manuscripts, we welcome research reports, product reviews, reports of new techniques, and findings of special significance to Asia and the Pacific Rim. Case studies that have significant novel original observations, are instructive, include adequate methodological details and provide conclusions. Workshop proceedings, meetings and book reviews, letters to the editor, and meeting announcements are encouraged along with relevant articles from authors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信